Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 2

Author:

Ton Minh That1,Ho Tri Huynh Quang2ORCID,Nguyen Viet Lan3,Pham Hung Manh4,Hoang Sy Van5ORCID,Vo Nhan Thanh6,Nguyen Thai Quoc3,Pham Linh Tran3,Mai Ton Duy7ORCID,Nguyen Thang Huy8ORCID

Affiliation:

1. Tam Duc Heart Hospital, Ho Chi Minh City, Vietnam

2. Surgical Intensive Care Unit, Heart Institute, Ho Chi Minh City, Vietnam

3. Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam

4. Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam; Hanoi Medical University, Hanoi, Vietnam

5. Cardiovascular Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam

6. Cardiovascular Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; Cardiovascular Center, Vinmec Hospital, Ho Chi Minh City, Vietnam

7. Hanoi Medical University, Hanoi, Vietnam; Stroke Center, Bach Mai Hospital, Hanoi, Vietnam; VNU-University of Medicine and Pharmacy, Hanoi, Vietnam

8. Cerebrovascular Disease Department, People’s 115 Hospital, Ho Chi Minh City, Vietnam; Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam

Abstract

Part 1 of this review provided an overview of AF in Vietnam, with a particular focus on primary and secondary stroke prevention. Part 2 explores the management of AF in special, high-risk and clinically common patient populations including those with renal impairment, diabetes, the elderly, and those with coronary artery disease. Furthermore, Part 2 addresses the challenges posed by patients with AF who have a bioprosthetic valve, a group situated in a grey area of consideration. Managing AF in these patient groups presents unique clinical challenges that require careful consideration. Physicians are tasked with addressing specific clinical questions to identify the optimal anticoagulation strategy for each individual. To inform these decisions, subgroup analyses from pivotal studies are presented alongside real-world data derived from clinical practice. By synthesising available information and considering the nuanced clinical context, the aim is to provide informed perspectives that align with current medical knowledge and contribute to the enhancement of patient care in these challenging scenarios.

Publisher

Radcliffe Media Media Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference87 articles.

1. Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263–72. https://doi.org/10.1378/chest.09-1584; PMID: 19762550.

2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373–498. https://doi.org/10.1093/eurheartj/ehaa612; PMID: 32860505.

3. Gómez-Outes A, Lagunar-Ruíz J, Terleira-Fernández AI, et al. Causes of death in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2016;68:2508–21. https://doi.org/10.1016/j.jacc.2016.09.944; PMID: 27931607.

4. Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the “atrial fibrillation better care” pathway in patients with atrial fibrillation: impact on clinical outcomes – a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022;122:406–14. https://doi.org/10.1055/a-1515-9630; PMID: 34020488.

5. Haas S, Camm JA, Harald D, et al. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clin Res Cardiol 2023;112:759–71. https://doi.org/10.1007/s00392-022-02079-y; PMID: 36094573.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3